Related Experiment Video

Updated: Jun 17, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

Fred Saad1, Allan Lipton

  • 1University of Montreal, CHU Montreal, 1560 Sherbrooke East, Montreal, Quebec, Canada. fred.saad@umontreal.ca

Cancer Treatment Reviews
|December 18, 2009
PubMed

Insights

SRC inhibitors show promise for treating bone metastases in advanced prostate and breast cancers. These targeted therapies may reduce tumor growth and bone pathology, offering new hope for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bone Biology

Background:

  • Prostate and breast cancers frequently metastasize to bone, leading to painful lesions and increased morbidity.
  • Tumor cells interact with bone cells (osteoclasts, osteoblasts), driving lesion development and disease progression.
  • SRC, a nonreceptor tyrosine kinase, is implicated in bone resorption, tumor growth, metastasis, and hormone resistance.

Purpose of the Study:

  • To evaluate SRC as a therapeutic target for bone metastases in advanced prostate and breast cancers.
  • To assess the potential of SRC-targeting agents in managing tumor-associated bone pathology.

Main Methods:

  • Review of preclinical data implicating SRC in cancer metastasis and bone pathology.
  • Analysis of preliminary data from Phase 1/2 clinical trials of SRC inhibitors (dasatinib, saracatinib, bosutinib) in solid tumors, including prostate and breast cancer patients with bone lesions.

Main Results:

  • Preclinical studies support SRC's role in key processes of bone metastasis.
  • Early clinical trial data indicate potential anti-tumor and bone-specific activity of SRC inhibitors in relevant patient populations.
  • SRC inhibitors are under investigation for advanced prostate and breast cancer with bone metastases.

Conclusions:

  • SRC is a rational therapeutic target for advanced prostate and breast cancers with bone metastases.
  • SRC inhibitors demonstrate preliminary efficacy and warrant further investigation in clinical trials.
  • Ongoing and future trials are crucial to confirm the clinical benefit of SRC inhibitors for patients with advanced disease.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: